<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of primary hypogonadism in males</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of primary hypogonadism in males</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of primary hypogonadism in males</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypogonadism in a man refers to a decrease in one or both of the two major functions of the testes: sperm production and testosterone production. These abnormalities usually result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism). (See  <a class="medical medical_review" href="/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor"</a> and  <a class="medical medical_review" href="/d/html/7470.html" rel="external">"Steroid 5-alpha-reductase 2 deficiency"</a>.)</p><p>The distinction between primary and secondary hypogonadism is made by measurement of the serum concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH):</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has primary hypogonadism if the serum testosterone concentration and the sperm count are below normal and the serum LH and FSH concentrations are above normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient has secondary hypogonadism if the serum testosterone concentration and the sperm count are subnormal and the serum LH and FSH concentrations are not elevated.</p><p></p><p>Primary hypogonadism differs from secondary hypogonadism in two ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypogonadism is more likely to be associated with a decrease in sperm production than in testosterone production. Although many testicular diseases damage both the seminiferous tubules and the Leydig cells, they usually damage the seminiferous tubules to a greater degree. As a consequence, the sperm count may be low and the serum FSH concentration normal or high, yet the serum testosterone concentration remains normal. In contrast, in secondary hypogonadism, there is a proportionate reduction in testosterone and sperm production.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypogonadism is more likely to be associated with gynecomastia, presumably due to the stimulatory effect of the supranormal serum FSH and LH concentrations on testicular aromatase activity. This results in increased conversion of testosterone to estradiol and enhanced testicular secretion of estradiol relative to testosterone.</p><p></p><p>The major causes of primary hypogonadism in males will be reviewed here (<a class="graphic graphic_table graphicRef53842" href="/d/graphic/53842.html" rel="external">table 1</a>). The causes of secondary hypogonadism and of male infertility, which may or may not be associated with hypogonadism, and the manifestations and diagnosis of hypogonadism in males are discussed separately. (See  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a> and  <a class="medical medical_review" href="/d/html/7473.html" rel="external">"Causes of male infertility"</a> and  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CONGENITAL ABNORMALITIES</span><span class="headingEndMark"> — </span>The clinical features of primary hypogonadism vary greatly, depending upon the specific cause and whether or not testosterone secretion is affected and when this occurs. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>If testosterone production is reduced during the first trimester in utero, the fetus will not be completely virilized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If testosterone production is normal during the first trimester but reduced during the third trimester in utero, male sexual differentiation will be normal, but the newborn infant will have a small penis, called micropenis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If testosterone production is reduced before the expected onset of puberty, full pubertal development will not occur.</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Klinefelter syndrome</span><span class="headingEndMark"> — </span>Klinefelter syndrome is the most common congenital abnormality causing primary hypogonadism, occurring in approximately 1 in 1000 live male births [<a href="#rid1">1</a>]. This syndrome is the clinical manifestation of a male who has an extra X chromosome. The most common genotype is <strong>47,XXY </strong>(<a class="graphic graphic_figure graphicRef72095" href="/d/graphic/72095.html" rel="external">figure 1</a>), but greater and lesser numbers of X chromosomes have also been reported, resulting in karyotypes such as 48,XXXY and 46,XY/47,XXY mosaicism [<a href="#rid2">2</a>]. The clinical features, diagnosis, and management of Klinefelter syndrome are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/13921.html" rel="external">"Clinical features, diagnosis, and management of Klinefelter syndrome"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Other chromosomal abnormalities</span><span class="headingEndMark"> — </span>A large number of other chromosomal abnormalities that result in testicular hypofunction have been reported. Included in this group of rare disorders are the 46,XY/XO and the 47,XYY karyotypes [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The 46,XY/XO karyotype leads to a syndrome characterized by short stature and features typical of Turner syndrome. The gonads vary from streak to dysgenetic to normal testes; as a result, the sexual phenotype varies from complete female to complete male. If the patient has both a streak gonad and a dysgenetic testis ("mixed gonadal dysgenesis"), the risk of gonadoblastoma is approximately 20 percent [<a href="#rid3">3</a>]. Gonadectomy should therefore be performed in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 47,XYY karyotype was initially thought to be associated with hypogonadism, but subsequent reports have not confirmed this relationship.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microdeletions in specific regions of the long arm of the Y chromosome are occur in up to 20 percent of men with azoospermia or severe oligospermia. Some of these men have no other testicular lesions, but others have cryptorchidism [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/7473.html" rel="external">"Causes of male infertility", section on 'Y chromosome and related defects'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Mutation in the FSH and LH receptor genes</span><span class="headingEndMark"> — </span>Another rare cause of primary hypogonadism is a mutation in the follicle-stimulating hormone (FSH) receptor gene [<a href="#rid5">5,6</a>]. One report described five men found to be homozygous for an inactivating mutation of the FSH receptor [<a href="#rid5">5</a>]. These subjects had variably low sperm counts and inhibin B concentrations and high serum FSH concentrations. Luteinizing hormone (LH) receptor mutations result in Leydig cell hypoplasia and testosterone deficiency in the first trimester in utero [<a href="#rid7">7</a>]. XY patients with mutations in <em>LHCGR</em> characteristically have female external genital appearance but lack a uterus and fallopian tubes; the epididymis and vas deferens may be present. (See  <a class="medical medical_review" href="/d/html/118045.html" rel="external">"Causes of differences of sex development", section on 'Conditions affecting androgen synthesis or response'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Cryptorchidism</span><span class="headingEndMark"> — </span>Cryptorchidism refers to testes that are undescended, specifically, to testes that are in the abdominal cavity or in the inguinal canal and cannot be manipulated manually to within the scrotum by the age of one year. In comparison, testes that can be manipulated manually into the scrotum are called retractile. The topic of cryptorchidism will be summarized very briefly here, but it is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2850.html" rel="external">"Undescended testes (cryptorchidism) in children: Clinical features and evaluation"</a> and  <a class="medical medical_review" href="/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management"</a> and  <a class="medical medical_review" href="/d/html/7473.html" rel="external">"Causes of male infertility", section on 'Cryptorchidism'</a>.)</p><p>Cryptorchidism may affect one or both testes. Some clinical consequences of cryptorchidism depend upon whether <strong>one or both testes</strong> are cryptorchid:</p><p class="bulletIndent1"><span class="glyph">●</span>If only one testis is undescended, the sperm count will be subnormal in 25 to 33 percent and the serum FSH concentration will be slightly elevated. The presence of these abnormalities suggests that both testes are abnormal, perhaps congenitally, even though only one fails to descend.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If both testes are undescended, the sperm count will usually be severely subnormal and the serum testosterone may also be reduced.</p><p></p><p>Men with a history of undescended testis also have an increased risk of developing testicular cancer compared with men in the general population in whom the age adjusted incidence is approximately 5.4 per 100,000. However, the magnitude of increased risk is poorly quantified. (See  <a class="medical medical_review" href="/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management", section on 'Testicular cancer'</a>.)</p><p>Treatment of cryptorchidism is also discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2850.html" rel="external">"Undescended testes (cryptorchidism) in children: Clinical features and evaluation"</a> and  <a class="medical medical_review" href="/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Disorders of androgen biosynthesis</span><span class="headingEndMark"> — </span>A congenital decrease in testosterone synthesis and secretion can result from mutations of the genes that encode the enzymes necessary for testosterone biosynthesis. These mutations, all rare, involve the cholesterol side-chain cleavage enzyme, 3 beta-hydroxysteroid dehydrogenase, and 17 alpha-hydroxylase, both of which are present in the adrenal glands as well as the testes, and 17 beta-hydroxysteroid dehydrogenase, which is present only in the testes. Each of these mutations results in decreased testosterone secretion, beginning in the first trimester of pregnancy, and therefore in incomplete virilization. (See  <a class="medical medical_review" href="/d/html/118045.html" rel="external">"Causes of differences of sex development", section on 'Reduced androgen synthesis'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Myotonic dystrophy</span><span class="headingEndMark"> — </span>Myotonic dystrophy, an autosomal dominant disorder that leads to muscle atrophy, is accompanied by hypogonadism that is usually not recognized until adulthood. Small testes and decreased sperm production are more common than decreased serum testosterone levels. In one study of 39 men with myotonic dystrophy, as an example, all had supranormal serum FSH concentrations, and approximately one-half had subnormal serum testosterone and supranormal serum LH concentrations [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/5147.html" rel="external">"Myotonic dystrophy: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Congenital anorchia</span><span class="headingEndMark"> — </span>This form of testicular regression occurs after 20 weeks of gestation, so that at birth, male sexual differentiation is normal but testes are absent and hypogonadism is severe. (See  <a class="medical medical_review" href="/d/html/118045.html" rel="external">"Causes of differences of sex development", section on 'Testicular dysfunction without atypical genital appearance'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Varicocele</span><span class="headingEndMark"> — </span>Varicosity of the venous plexus within the scrotum, called a varicocele, has long been considered a possible cause of damage to the seminiferous tubules and thereby of infertility. As a result, ligation of varicoceles has long been practiced as a treatment for infertile men, although available data do not support this practice. This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7452.html" rel="external">"Treatments for male infertility", section on 'Surgical repair of varicocele'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">ACQUIRED DISEASES</span><span class="headingEndMark"> — </span>The manifestations of acquired causes of primary hypogonadism also depend upon whether sperm production, testosterone secretion, or both are impaired and, if testosterone secretion is diminished, when this occurs. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased sperm production results in infertility</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced testosterone secretion during childhood is associated with incomplete pubertal changes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diminished testosterone secretion during adulthood leads to decreases in energy, libido, sexual hair, muscle mass, and bone mineral density</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Mumps orchitis is the infection most closely associated with testicular damage. Orchitis is a much more common manifestation when mumps occurs in adulthood than in childhood. The median age of men with mumps orchitis in one study was 29 years, compared with age eight of all patients with mumps [<a href="#rid9">9</a>]. The incidence of mumps orchitis should decrease because of the widespread use of the mumps vaccine.</p><p>Testicular involvement of mumps causes painful swelling of the testes, followed by atrophy. The seminiferous tubules are almost always severely affected, often resulting in infertility, especially when both testes are involved; the Leydig cells also may be damaged, resulting in decreased testosterone production [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/8310.html" rel="external">"Mumps", section on 'Orchitis or oophoritis'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Radiation</span><span class="headingEndMark"> — </span>Direct radiation to the testes, as in treatment for leukemia, will damage the testes [<a href="#rid11">11</a>]. Even indirect radiation to the testes that are shielded (as with radiation to the inguinal lymph nodes for lymphoma) will damage the seminiferous tubules [<a href="#rid12">12</a>]. The degree of damage is proportionate to the amount of radiation exposure.</p><p>Radioactive iodide has been reported to cause a decrease in the sperm count when doses of several hundred mCi are administered to treat thyroid cancer [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/7473.html" rel="external">"Causes of male infertility", section on 'Drugs and radiation'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Alkylating and antineoplastic agents</span><span class="headingEndMark"> — </span>Alkylating agents, such as <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, can damage the seminiferous tubules to a degree sufficient to cause azoospermia and markedly elevated serum follicle-stimulating hormone (FSH) concentrations [<a href="#rid14">14,15</a>]. As with radiation, the damage is proportionate to the extent and duration of treatment. Long-term follow-up of men treated in childhood suggests that many patients recover normal spermatogenesis and fertility [<a href="#rid15">15</a>]. Less commonly, testosterone secretion is also impaired, leading to a decrease in the serum concentration of testosterone and increase in that of luteinizing hormone (LH) [<a href="#rid16">16</a>]. Concurrent administration of testosterone might protect against long-term gonadal injury in adults. (See  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases", section on 'Gonadal toxicity'</a> and  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> also can decrease the sperm count, but the count typically recovers, at least partially. In one study, as an example, the changes in sperm count were assessed in 89 men with testicular germ-cell tumors who were treated with unilateral orchiectomy and either cisplatin- or carboplatin-based chemotherapy [<a href="#rid17">17</a>]. The sperm count was normal in 64 percent at one year and 80 percent at five years. Recovery was less likely when cisplatin was administered for more than four cycles.</p><p>Other chemotherapeutic agents can also cause some degree of seminiferous tubular damage, but the effect is less prominent than that of alkylating agents. (See  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Ketoconazole</span><span class="headingEndMark"> — </span>The antifungal drug <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> directly inhibits testosterone biosynthesis, thereby causing testosterone deficiency [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Chronic glucocorticoid use can also lower testosterone levels by approximately one-third; the mechanism is not clear, but inhibition may occur at both the testis and pituitary [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Environmental toxins (endocrine-disrupting chemicals)</span><span class="headingEndMark"> — </span>Many environmental toxins have been demonstrated to cause decreased spermatogenesis in laboratory animals or in vitro. The nematocide <strong>dibromochloropropane</strong> is known to decrease spermatogenesis in men in vivo and has been banned [<a href="#rid20">20</a>]. Although several toxins, referred to as endocrine-disrupting chemicals, have been associated with abnormalities in one semen parameter or another, no one agent has been consistently shown to affect any one parameter [<a href="#rid21">21</a>], and therefore, one cannot state that any one agent is a cause of testicular damage in men. (See  <a class="medical medical_review" href="/d/html/113968.html" rel="external">"Endocrine-disrupting chemicals"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Trauma</span><span class="headingEndMark"> — </span>Trauma to the testes can be sufficiently severe to damage both seminiferous tubules and Leydig cells.</p><p class="headingAnchor" id="H20"><span class="h2">Testicular torsion</span><span class="headingEndMark"> — </span>Testicular torsion is one of the most common reasons for the loss of a testicle before puberty. Testicular torsion is a twisting of the testis on the spermatic cord, which results in acute loss of the blood supply to the testis. The testis can die from lack of blood if the torsion does not remit spontaneously or is not corrected surgically within a few hours. The degree of damage depends upon the duration of the torsion. Torsion lasting more than eight hours can lead to sufficient damage to the seminiferous tubules to lower the sperm count [<a href="#rid22">22</a>]. Even when the torsion involves only one testis, both testes may be damaged. How this might occur is not known. (See  <a class="medical medical_review" href="/d/html/6446.html" rel="external">"Causes of scrotal pain in children and adolescents", section on 'Testicular torsion'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Bilateral orchiectomy</span><span class="headingEndMark"> — </span>Orchiectomy is standard treatment for testicular cancer, which is often bilateral, although it often occurs at different times on each side.</p><p class="headingAnchor" id="H22"><span class="h2">Autoimmune damage</span><span class="headingEndMark"> — </span>Many men with idiopathic infertility have antisperm antibodies. It is not known, however, if these antibodies are the result of an autoimmune process or a response to damage by some other mechanism [<a href="#rid23">23</a>].</p><p>The hypogonadism that accompanies autoimmune polyglandular disease is also characterized by hypothyroidism and hypoadrenalism. It is much less common than idiopathic infertility, but it is more likely to be the result of an autoimmune process [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 2 (polygenic)'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Chronic, systemic diseases</span><span class="headingEndMark"> — </span>Many chronic, systemic illnesses cause hypogonadism both by a direct testicular effect and by decreasing gonadotropin secretion.</p><p class="headingAnchor" id="H24"><span class="h3">Cirrhosis</span><span class="headingEndMark"> — </span>Cirrhosis is occasionally associated with hypogonadism, as manifested by a reduction in the serum testosterone concentration. More than one mechanism appears to be involved. In some cases, primary gonadal injury appears to be more prominent, as suggested by increased serum FSH and LH concentrations [<a href="#rid25">25,26</a>]. In others, suppression of hypothalamic or pituitary function appears to play a primary role, as suggested by serum LH concentrations that are not elevated [<a href="#rid26">26</a>]. Hypogonadism due to cirrhosis is rapidly corrected following liver transplantation [<a href="#rid27">27</a>].</p><p>Acute alcohol ingestion also may cause secondary hypogonadism, as manifested by subnormal serum testosterone concentration levels without increases in either LH or FSH [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H25"><span class="h3">Chronic kidney disease</span><span class="headingEndMark"> — </span>Severe chronic kidney disease may also be associated with hypogonadism. One study, as an example, evaluated 35 men with creatinine clearances of below 4 mL/min per 1.73 m<sup>2</sup>; the mean (±SE) serum testosterone concentration was 469±58 ng/dL (16.3±2.0 nmol/L), compared with 622±130 ng/dL (21.6±4.5 nmol/L) in normal men [<a href="#rid29">29</a>]. Several observations suggested that this was due to primary hypogonadism:</p><p class="bulletIndent1"><span class="glyph">●</span>Germinal cells, as seen on histologic sections of testicular biopsies in 15 of the men, were subnormal compared with normal men</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mean serum FSH and LH concentrations were supranormal, while the serum testosterone response to exogenous human chorionic gonadotropin (hCG) was impaired</p><p></p><p>Another study evaluated men with chronic kidney disease who were being treated by hemodialysis and then underwent renal transplantation [<a href="#rid30">30</a>]. Some of the patients had similar findings to the previous study consisting of abnormalities in testicular biopsy, a low sperm count, and high serum FSH and LH concentrations. These findings, which were consistent with primary hypogonadism, were corrected by renal transplantation. However, the improvement in sperm count and testosterone concentration was preceded by a surge in FSH release, suggesting that transplantation corrected a concurrent impairment in hypothalamic or pituitary function. (See  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males", section on 'Chronic, systemic illness'</a>.)</p><p class="headingAnchor" id="H26"><span class="h3">HIV</span><span class="headingEndMark"> — </span>Men who have human immunodeficiency virus (HIV) infection may be hypogonadal to some degree, as judged by generally lower serum testosterone concentrations than men without HIV [<a href="#rid31">31</a>]. However, the serum FSH and LH can be elevated or not, indicating both primary and secondary hypogonadism. The frequency with which hypogonadism accompanies HIV infection and its severity appear to have diminished since the introduction of antiretroviral therapy. (See  <a class="medical medical_review" href="/d/html/13969.html" rel="external">"Hypogonadism in males with HIV"</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Idiopathic</span><span class="headingEndMark"> — </span>Primary hypogonadism is often idiopathic, whether it is severe, resulting in testosterone deficiency and azoospermia, or mild, resulting only in oligospermia/azoospermia and an elevated FSH.</p><p class="headingAnchor" id="H3839398413"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115208.html" rel="external">"Society guideline links: Male infertility or hypogonadism"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>Hypogonadism in a male refers to a decrease in either of the two major functions of the testes: sperm production and testosterone production. These abnormalities usually result from disease of the testes (primary hypogonadism), disease of the pituitary or hypothalamus (secondary hypogonadism), or, more rarely, a defect in the ability to respond to testosterone. (See  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a> and  <a class="medical medical_review" href="/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor"</a>.)</p><p>The distinction between primary and secondary hypogonadism is made by measurement of the serum concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH):</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has primary hypogonadism if the serum testosterone concentration and the sperm count are below normal and the serum LH and FSH concentrations are above normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient has secondary hypogonadism if the serum testosterone concentration and the sperm count are subnormal and the serum LH and FSH concentrations are normal or reduced.</p><p></p><p>Primary hypogonadism differs from secondary hypogonadism in two ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypogonadism is more likely to be associated with a decrease in sperm production than in testosterone production. Although many testicular diseases damage both the seminiferous tubules and the Leydig cells, they usually damage the seminiferous tubules to a greater degree.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypogonadism is more likely to be associated with gynecomastia, presumably due to the stimulatory effect of the supranormal serum FSH and LH concentrations on testicular aromatase activity. This results in increased conversion of testosterone to estradiol and enhanced testicular secretion of estradiol relative to testosterone.</p><p></p><p>Primary hypogonadism may be due to congenital abnormalities or acquired diseases.</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital abnormalities include: Klinefelter syndrome (the most common congenital cause), FSH and LH receptor mutations, cryptorchidism, disorders of androgen biosynthesis, and myotonic dystrophy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acquired diseases include: infection (mumps orchitis); radiation and chemotherapy; trauma; testicular torsion; chronic, systemic diseases; environmental toxins; <a class="drug drug_general" data-topicid="10291" href="/d/drug information/10291.html" rel="external">suramin</a>; <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>; glucocorticoids; autoimmune damage; and human immunodeficiency virus (HIV). Unfortunately, many cases of primary hypogonadism remain unexplained (idiopathic).</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 2003; 88:622.</a></li><li><a class="nounderline abstract_t">Paulsen CA, Gordon DL, Carpenter RW, et al. Klinefelter's syndrome and its variants: a hormonal and chromosomal study. Recent Prog Horm Res 1968; 24:321.</a></li><li><a class="nounderline abstract_t">Simpson JL. Male pseudohermaphroditism: genetics and clinical delineation. Hum Genet 1978; 44:1.</a></li><li><a class="nounderline abstract_t">Foresta C, Moro E, Garolla A, et al. Y chromosome microdeletions in cryptorchidism and idiopathic infertility. J Clin Endocrinol Metab 1999; 84:3660.</a></li><li><a class="nounderline abstract_t">Tapanainen JS, Aittomäki K, Min J, et al. Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. Nat Genet 1997; 15:205.</a></li><li><a class="nounderline abstract_t">Simoni M, Gromoll J, Höppner W, et al. Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms. J Clin Endocrinol Metab 1999; 84:751.</a></li><li><a class="nounderline abstract_t">Latronico AC, Anasti J, Arnhold IJ, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996; 334:507.</a></li><li><a class="nounderline abstract_t">Harper P, Penny R, Foley TP Jr, et al. Gonadal function in males with myotonic dystrophy. J Clin Endocrinol Metab 1972; 35:852.</a></li><li><a class="nounderline abstract_t">Beard CM, Benson RC Jr, Kelalis PP, et al. The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clin Proc 1977; 52:3.</a></li><li><a class="nounderline abstract_t">Aiman J, Brenner PF, MacDonald PC. Androgen and estrogen production in elderly men with gynecomastia and testicular atrophy after mumps orchitis. J Clin Endocrinol Metab 1980; 50:380.</a></li><li><a class="nounderline abstract_t">Brauner R, Czernichow P, Cramer P, et al. Leydig-cell function in children after direct testicular irradiation for acute lymphoblastic leukemia. N Engl J Med 1983; 309:25.</a></li><li><a class="nounderline abstract_t">Shapiro E, Kinsella TJ, Makuch RW, et al. Effects of fractionated irradiation of endocrine aspects of testicular function. J Clin Oncol 1985; 3:1232.</a></li><li><a class="nounderline abstract_t">Handelsman DJ, Turtle JR. Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 1983; 18:465.</a></li><li><a class="nounderline abstract_t">Qureshi MS, Pennington JH, Goldsmith HJ, Cox PE. Cyclophosphamide therapy and sterility. Lancet 1972; 2:1290.</a></li><li><a class="nounderline abstract_t">Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 1985; 291:1457.</a></li><li><a class="nounderline abstract_t">Friedman NM, Plymate SR. Leydig cell dysfunction and gynaecomastia in adult males treated with alkylating agents. Clin Endocrinol (Oxf) 1980; 12:553.</a></li><li><a class="nounderline abstract_t">Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15:239.</a></li><li><a class="nounderline abstract_t">Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142:2137.</a></li><li><a class="nounderline abstract_t">Odell WD. Testosterone treatment of men treated with glucocorticoids. Arch Intern Med 1996; 156:1133.</a></li><li><a class="nounderline abstract_t">Whorton D, Krauss RM, Marshall S, Milby TH. Infertility in male pesticide workers. Lancet 1977; 2:1259.</a></li><li><a class="nounderline abstract_t">Sharma A, Mollier J, Brocklesby RWK, et al. Endocrine-disrupting chemicals and male reproductive health. Reprod Med Biol 2020; 19:243.</a></li><li><a class="nounderline abstract_t">Thomas WE, Cooper MJ, Crane GA, et al. Testicular exocrine malfunction after torsion. Lancet 1984; 2:1357.</a></li><li><a class="nounderline abstract_t">Shulman S. Antisperm antibodies and subfertility? Fertil Steril 1994; 62:1283.</a></li><li><a class="nounderline abstract_t">Uibo R, Aavik E, Peterson P, et al. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab 1994; 78:323.</a></li><li><a class="nounderline abstract_t">Baker HW, Burger HG, de Kretser DM, et al. A study of the endocrine manifestations of hepatic cirrhosis. Q J Med 1976; 45:145.</a></li><li><a class="nounderline abstract_t">Van Thiel DH, Lester R, Sherins RJ. Hypogonadism in alcoholic liver disease: evidence for a double defect. Gastroenterology 1974; 67:1188.</a></li><li><a class="nounderline abstract_t">Guéchot J, Chazouillères O, Loria A, et al. Effect of liver transplantation on sex-hormone disorders in male patients with alcohol-induced or post-viral hepatitis advanced liver disease. J Hepatol 1994; 20:426.</a></li><li><a class="nounderline abstract_t">Gordon GG, Altman K, Southren AL, et al. Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. N Engl J Med 1976; 295:793.</a></li><li><a class="nounderline abstract_t">Holdsworth S, Atkins RC, de Kretser DM. The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977; 296:1245.</a></li><li><a class="nounderline abstract_t">Lim VS, Fang VS. Gonadal dysfunction in uremic men. A study of the hypothalamo-pituitary-testicular axis before and after renal transplantation. Am J Med 1975; 58:655.</a></li><li><a class="nounderline abstract_t">Rochira V, Guaraldi G. Hypogonadism in the HIV-infected man. Endocrinol Metab Clin North Am 2014; 43:709.</a></li></ol></div><div id="topicVersionRevision">Topic 7459 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12574191" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4883112" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Klinefelter's syndrome and its variants: a hormonal and chromosomal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/711236" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Male pseudohermaphroditism: genetics and clinical delineation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523011" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Y chromosome microdeletions in cryptorchidism and idiopathic infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9020851" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022448" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559204" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4634486" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gonadal function in males with myotonic dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/609284" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7354122" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Androgen and estrogen production in elderly men with gynecomastia and testicular atrophy after mumps orchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6406893" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Leydig-cell function in children after direct testicular irradiation for acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3928830" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of fractionated irradiation of endocrine aspects of testicular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6409459" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4117814" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cyclophosphamide therapy and sterility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3933709" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long term effects of cyclophosphamide on testicular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6772358" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Leydig cell dysfunction and gynaecomastia in adult males treated with alkylating agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996148" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fertility after chemotherapy for testicular germ cell cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6291475" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ketoconazole blocks testosterone synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639006" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Testosterone treatment of men treated with glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/73955" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Infertility in male pesticide workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32684823" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Endocrine-disrupting chemicals and male reproductive health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6150364" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Testicular exocrine malfunction after torsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7958001" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antisperm antibodies and subfertility?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8106620" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/769039" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A study of the endocrine manifestations of hepatic cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4430432" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypogonadism in alcoholic liver disease: evidence for a double defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8014456" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of liver transplantation on sex-hormone disorders in male patients with alcohol-induced or post-viral hepatitis advanced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/958274" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/870823" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The pituitary-testicular axis in men with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1093402" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gonadal dysfunction in uremic men. A study of the hypothalamo-pituitary-testicular axis before and after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25169563" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypogonadism in the HIV-infected man.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
